** Shares of drugmaker Madrigal Pharmaceuticals MDGL.O rise 13.8% to $352.3
** Co reports Q4 sales of $103.3 mln from its fatty liver disease drug Rezdiffra, beating analysts' estimate of $71.95 mln as per data compiled by LSEG
** Two-year data from a late-stage study evaluating Rezdiffra shows it helped significantly reduce liver stiffness in patients with metabolic dysfunction-associated steatohepatitis (MASH)
** Says 51% of patients enrolled in the trial achieved 25% or greater reduction in liver stiffness -MDGL
** Significant reduction of liver stiffness has been associated with reduced progression to end-stage liver disease -MDGL
** MASH is a serious condition that causes excess build up of fat in the liver and causes inflammation and fibrosis, or scarring, of the organ
** Stock has risen 33% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.